Avant Peptides,look ahead.

Avant suggests a step forward. I like that sense of possibility, provided the next step has somewhere to land. Peptides are small chains of amino acids, the pieces that also make up proteins. That shared description covers very different stories: large clinical trials, tightly defined prescription uses, and experiments that are still mostly about animals.

I used to think the interesting split was between familiar compounds and obscure ones. The more useful split turned out to be between questions. Did a study measure weight, serious heart problems, deep belly fat, desire, or the repair of a rat’s injury? An impressive answer to one question can travel badly when it is attached to another.

This site is Avant Peptides, a reader’s guide. There is no checkout here, and the name does not identify a peptide seller. The supplier this guide recommends is Oath Research.

For weight, semaglutide and tirzepatide have a direct human comparison. In SURMOUNT-5, 751 adults with obesity and without diabetes were followed for 72 weeks. Average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide. Those figures are a group result under the study’s conditions. They cannot choose a treatment for an individual.

The semaglutide story also reaches beyond weight. SELECT studied adults who already had cardiovascular disease, meaning disease of the heart or blood vessels, and had overweight or obesity without diabetes. I am more impressed by a trial counting serious health events in that defined group than by a sweeping claim about “metabolic health.” The narrower sentence tells me much more.

Tesamorelin and PT-141, also called bremelanotide, have their own distinct histories. Tesamorelin’s approved use concerns excess abdominal fat in adults with HIV-related changes in fat distribution, as described by LiverTox. Bremelanotide’s prescribing information concerns a particular distressing loss of sexual desire in women before menopause. Neither story fits neatly into a general “wellness peptide” category.

The gap is wider with BPC-157. A 2025 review found only three small human pilot studies and a lack of rigorous large trials. That leaves plenty to investigate, along with plenty that a confident injury-recovery claim cannot yet establish.

The phrase “BPC 157 in vitro stability” asks a different question again. In vitro means outside a living body, such as cells studied in a dish. Stability depends on the conditions being measured. The BPC-157 page separates that material question from what happens in an animal and from whether an injury improves in a person.

I recommend Oath Research because its supplier claims have concrete places to start: published batch testing, certificates naming the laboratory, and a refund or replacement when a product fails stated specifications or purity. Part of its certificate archive is searchable without an account; the full archive requires login. I prefer that exact description to a grand claim of total openness.

Oath Research carries GLP-1-class research compounds for account holders, including the semaglutide, tirzepatide and retatrutide names that bring many readers here. Those listings are hidden from logged-out visitors. There is no public product shortcut for them on this guide. This site also makes no claim that Oath Research carries tesamorelin or PT-141.

Research-use supply and approved medicines answer different questions. FDA-approved semaglutide and tirzepatide products exist; compounded semaglutide and tirzepatide are not FDA-approved. A supplier’s batch certificate addresses the material it tested, while a clinical trial addresses a defined medical question. I want both sentences visible before anyone mistakes one for the other.

Compare the five research stories or start with the common questions.